Multifocal Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Presenting on Face and Chest: Complete Remission With R-CHOP
ABSTRACT: Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is an aggressive subtype of primary cutaneous B-cell lymphoma that predominantly affects the lower extremities of elderly individuals. We report a rare case of a 79-year-old woman presenting with rapidly enlarging, erythematous-to-violaceous tumors and plaques on the face, chest, left upper arm, and upper back, an uncommon non-leg manifestation of PCDLBCL-LT, confirmed by histopathology and immunohistochemistry. The patient was successfully treated with six cycles of the rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, achieving complete remission with no relapse during 1.5 years of follow-up. This case emphasizes that PCDLBCL-LT can present in locations outside the legs, highlighting the need for early recognition and systemic therapy in atypical locations.
Authors
- Zoi Papadopoulou (ORCID: https://orcid.org/0000-0003-2575-0484)
- Michael Panagiotidis
- Maria Daviti (ORCID: https://orcid.org/0000-0002-0176-6804)
- Michael Arabatzis (ORCID: https://orcid.org/0000-0003-4018-8784)
- Elena Sotiriou (ORCID: https://orcid.org/0000-0001-6235-4718)
- Panagiotis Kalmoukos (ORCID: https://orcid.org/0009-0000-7124-2785)
- Nikolaos Chaitidis (ORCID: https://orcid.org/0000-0003-0786-0129)
- Nikolaos Tsiaras
- Efstratios Vakirlis (ORCID: https://orcid.org/0000-0002-8814-3561)
- Kalliopi Gianna
- Iclal Gerdemeli
- Stavritsa-Taxiarchoula Varvara
Institutions
- Aristotle University of Thessaloniki (GR)
- Papageorgiou General Hospital (GR)
- Ippokrateio General Hospital of Thessaloniki (GR)
- KAT General Hospital of Attica (GR)
Publication Details
- Journal
- American Journal of Dermatopathology
- Published
- 2026-08-21
- DOI
- https://doi.org/10.1097/dad.0000000000003410
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00